SGLT-2 inhibitors as novel treatments of multiple organ fibrosis

Junpei Hu; Jianhui Teng; Shan Hui; Lihui Liang

doi:10.1016/j.heliyon.2024.e29486

SGLT-2 inhibitors as novel treatments of multiple organ fibrosis

Heliyon. 2024 Apr 11;10(8):e29486. doi: 10.1016/j.heliyon.2024.e29486. eCollection 2024 Apr 30.

Authors

Junpei Hu¹, Jianhui Teng², Shan Hui¹, Lihui Liang¹

Affiliations

¹ Department of Geriatrics, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, China.
² Department of Geriatrics, Hunan Provincial People's Hospital, China.

Abstract

Fibrosis, a significant health issue linked to chronic inflammatory diseases, affects various organs and can lead to serious damage and loss of function. Despite the availability of some treatments, their limitations necessitate the development of new therapeutic options. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), known for their glucose-lowering ability, have shown promise in offering protective effects against fibrosis in multiple organs through glucose-independent mechanisms. This review explores the anti-fibrotic potential of SGLT2i across different tissues, providing insights into their underlying mechanisms and highlighting recent research advancements. The evidence positions SGLT2i as a potential future treatments for fibrotic diseases.

Keywords: Anti-fibrotic effects; Fibrosis; Mechanism; SGLT-2 inhibitors; Treatment strategies.

Publication types

Review